Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer

IF 5.1 4区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Precision Clinical Medicine Pub Date : 2020-02-18 DOI:10.1093/pcmedi/pbaa005

Huanji Xu, Sheng Zhou, Q. Hu, D. Cao

{"title":"Apatinib treatment for unresectable gastrointestinal stromal tumor with synchronous gastric cancer","authors":"Huanji Xu, Sheng Zhou, Q. Hu, D. Cao","doi":"10.1093/pcmedi/pbaa005","DOIUrl":null,"url":null,"abstract":"Abstract Nearly one-fifth of patients diagnosed with gastrointestinal stromal tumors (GISTs) simultaneously experience a second primary tumor. In particular, coexistence of gastric GISTs and gastric cancer is relatively more common. However, the optimal treatment for advanced GIST with gastric cancer is largely unknown. We report a case of simultaneous occurrence of gastric GIST and gastric cancer that benefited from apatinib. After first-line imatinib and S-1 treatment for 6 months, the GIST and the gastric cancer both progressed. The patient was then treated with apatinib, exhibiting a partial response (PR) both in the GIST and the gastric cancer at 7 months, and continuous PR so far with well-controlled toxic effects of hypertension. Progression-free survival reached 10 months. In view of the relatively high incidence of advanced GIST with synchronous gastric cancer, therapy to simultaneously treat the two kinds of tumors is urgently needed. Apatinib provides promising and well-tolerated therapy for GISTs with synchronous gastric cancer refractory to chemotherapy combined with imatinib.","PeriodicalId":33608,"journal":{"name":"Precision Clinical Medicine","volume":"18 1","pages":"67 - 70"},"PeriodicalIF":5.1000,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/pcmedi/pbaa005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 4

Abstract

Abstract Nearly one-fifth of patients diagnosed with gastrointestinal stromal tumors (GISTs) simultaneously experience a second primary tumor. In particular, coexistence of gastric GISTs and gastric cancer is relatively more common. However, the optimal treatment for advanced GIST with gastric cancer is largely unknown. We report a case of simultaneous occurrence of gastric GIST and gastric cancer that benefited from apatinib. After first-line imatinib and S-1 treatment for 6 months, the GIST and the gastric cancer both progressed. The patient was then treated with apatinib, exhibiting a partial response (PR) both in the GIST and the gastric cancer at 7 months, and continuous PR so far with well-controlled toxic effects of hypertension. Progression-free survival reached 10 months. In view of the relatively high incidence of advanced GIST with synchronous gastric cancer, therapy to simultaneously treat the two kinds of tumors is urgently needed. Apatinib provides promising and well-tolerated therapy for GISTs with synchronous gastric cancer refractory to chemotherapy combined with imatinib.

查看原文本刊更多论文

阿帕替尼治疗不可切除的胃肠道间质瘤合并同步胃癌

近五分之一的胃肠道间质瘤(gist)患者同时发生第二原发肿瘤。尤其是胃间质间质瘤与胃癌共存的情况相对更为常见。然而，晚期GIST合并胃癌的最佳治疗方法在很大程度上是未知的。我们报告一例同时发生的胃间质瘤和胃癌，受益于阿帕替尼。一线伊马替尼和S-1治疗6个月后，GIST和胃癌均进展。患者随后接受阿帕替尼治疗，在7个月时胃肠道间质瘤和胃癌均出现部分缓解(PR)，并且到目前为止持续缓解，高血压的毒性作用得到了很好的控制。无进展生存期达到10个月。鉴于晚期GIST合并同步胃癌的发生率较高，迫切需要两种肿瘤同时治疗的治疗方法。阿帕替尼为化疗联合伊马替尼难治的gist伴同步胃癌提供了有希望且耐受性良好的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Precision Clinical Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

10.80

自引率

0.00%

发文量

审稿时长

5 weeks

期刊介绍： Precision Clinical Medicine (PCM) is an international, peer-reviewed, open access journal that provides timely publication of original research articles, case reports, reviews, editorials, and perspectives across the spectrum of precision medicine. The journal's mission is to deliver new theories, methods, and evidence that enhance disease diagnosis, treatment, prevention, and prognosis, thereby establishing a vital communication platform for clinicians and researchers that has the potential to transform medical practice. PCM encompasses all facets of precision medicine, which involves personalized approaches to diagnosis, treatment, and prevention, tailored to individual patients or patient subgroups based on their unique genetic, phenotypic, or psychosocial profiles. The clinical conditions addressed by the journal include a wide range of areas such as cancer, infectious diseases, inherited diseases, complex diseases, and rare diseases.